论文信息 - COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus - 字舞流文

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

E. Montserrat | J. Delgado | K. Stamatopoulos | R. Foà | T. Chatzikonstantinou | D. Rossi | A. Cuneo | A. Kater | R. Marasca | C. Tam | M. Varettoni | A. Chiarenza | G. Rossi | M. Gentile | M. Šimkovič | A. Ferrari | L. Trentin | M. Špaček | D. Bron | C. Niemann | L. Laurenti | A. Rambaldi | M. Papaioannou | M. Zdrenghea | Y. Herishanu | L. Farina | T. Herold | M. Levin | E. van der Spek | P. Ghia | N. Stavroyianni | M. Motta | E. Nikitin | L. Scarfò | F. Mauro | P. Sportoletti | Amit Shrestha | M. Yassin | L. De Paoli | M. Doubek | M. Coscia | G. Rigolin | G. del Poeta | G. Barna | S. Iyengar | T. Munir | G. Reda | J. Marquet | F. Quaglia | A. Janssens | S. Kersting | M. Baile | M. Dimou | J. García-Marco | J. Hernández‐Rivas | F. Miras | M. Marchetti | O. Jakšić | E. Wąsik-Szczepanek | Y. Hakobyan | N. Shah | M. R. De Paolis | L. Orsucci | M. Foglietta | C. Vitale | R. Ruchlemer | E. Vandenberghe | G. Quaresmini | G. Itchaki | B. Pocali | L. Malerba | E. Gimeno | A. Enrico | V. Strugov | O. Stanca | V. Popov | Enrico Lista | M. Andres | C. Cuéllar-García | O. Kalashnikova | Gimena dos Santos | M. Ortiz Pareja | E. Lista | F. M. Quaglia | Talha Munir | Barbara Pocali | Gimena dos Santos

[1] S. Jamal,et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. , 2021, Blood reviews.

[2] J. Byrd,et al. How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic , 2020, HemaSphere.

[3] R. Foà,et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report , 2020, Blood.

[4] L. Staudt,et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 , 2020, Science Immunology.

[5] Jun Yu Li,et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[6] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[7] E. Montserrat,et al. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report , 2020, Leukemia.

[8] M. Piris,et al. Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies , 2020, British journal of haematology.

[9] G. Gao,et al. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[11] R. Gale,et al. COVID-19 in persons with haematological cancers , 2020, Leukemia.

[12] S. Treon,et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients , 2020, Blood.

[13] Jun Liu,et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China , 2020, European Respiratory Journal.

[14] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[15] M. Zheng,et al. COVID-19 in a patient with chronic lymphocytic leukaemia , 2020, The Lancet Haematology.

[16] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[17] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[18] M. Luppi,et al. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. , 2019, Blood reviews.

[19] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[20] P. Moss,et al. Perturbation of the normal immune system in patients with CLL. , 2015, Blood.

[21] J. Gribben,et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.